# Vasopressors & Fluids â€“ Landmark Trials

## VASST Trial (2008)
**Journal:** NEJM  
**Design:** Multicenter RCT, n=778  
**Population:** Septic shock  
**Intervention:** Vasopressin + norepinephrine  
**Comparator:** Norepinephrine alone  
**Primary Outcome:** 28-day mortality  
**Key Results:** No overall difference; benefit in less severe shock  
**Reference:** Russell JA et al., NEJM 2008. PubMed

## ATHOS-3 (2017)
**Journal:** NEJM  
**Design:** Multicenter RCT, n=344  
**Population:** Vasodilatory shock  
**Intervention:** Angiotensin II  
**Comparator:** Placebo  
**Primary Outcome:** MAP response at 3h  
**Key Results:** Higher MAP response with AngII  
**Reference:** Khanna A et al., NEJM 2017. PubMed

## FEAST Trial (2011)
**Journal:** NEJM  
**Population:** Pediatric shock (for reference only)  
**Intervention:** Fluid bolus  
**Key Results:** Harmful in resource-limited settings  
